Novolin R (regular human insulin)
Cheap OTC short-acting insulin used by bodybuilders post-workout for "nutrient partitioning" — claimed to drive glucose, amino acids, and creatine into muscle. | Compound
Aliases (5)
▸ Overview TL;DR
Cheap OTC short-acting insulin used by bodybuilders post-workout for "nutrient partitioning" — claimed to drive glucose, amino acids, and creatine into muscle. The actual evidence for hypertrophy benefit is weak; the lethal-overdose risk is well-documented (multiple deaths in fitness community). For a 20-year-old with healthy beta cells, this is a SKIP-PERMANENT.
▸ Mechanism of action
Regular insulin = identical to endogenous human insulin (51 aa, two chains A+B). Binds insulin receptor tyrosine kinase → autophosphorylation → IRS-1/2 → PI3K → Akt → GLUT4 translocation (muscle, adipose) → glucose uptake. Also activates mTORC1 (modestly) → muscle protein synthesis. Suppresses lipolysis and hepatic glucose output.
Hexameric formulation in vial dissociates after SC injection; onset 30 min, peak 2-4 hr, duration 5-8 hr. Slower than analog rapid-acting insulins (lispro, aspart, glulisine).
▸ Pharmacokinetics No data
▸ What to expect Generic
- 1Week 1Tolerability and dose-response.
- 2Week 2-4Early effect window.
- 3Week 4-8Peak benefit assessment.
- 4Week 8+Cycle decision point.
▸ Side effects + safety
- Common (in all users): Hypoglycemia symptoms if mistimed
- Less common: Injection-site lipohypertrophy
- Rare-serious — and the entire reason for SKIP-PERMANENT:
- Severe hypoglycemia → coma → death. Multiple documented bodybuilder deaths (Ghent Wakefield 1998 case series and many since). Brain injury possible from prolonged hypoglycemia even if not fatal.
- Iatrogenic insulin reaction during sleep — bodybuilders who dose evening then nap have died because hypoglycemia symptoms don't wake them.
- Counter-regulation failure — repeated hypoglycemia blunts glucagon response, making subsequent episodes more dangerous (hypoglycemia unawareness).
- Long-term: Insulin promotes adipose lipogenesis and is mitogenic at high doses — chronic supraphysiologic insulin exposure may increase cancer risk (epidemiologic, debated).
- Edema, hypokalemia at higher doses (insulin shifts K+ intracellularly).
- Specific watch periods: Every dose. There is no safe interval.
▸Interactions2 compounds
- In bodybuilding context (DO NOT REPLICATE):SynergisticOften stacked with HGH, IGF-1, AAS for "GH-insulin-AAS triad." Compounds risk dramatically.
- Beta blockersAvoid(mask hypoglycemia symptoms — life-threatening combo)
▸References5 sources
Evans PJ, Lynch RM (2003) — Insulin as a drug of abuse in body building. Br J Sports Med
2003PMID 12782561, foundational case-series review
Dawson RT, Harrison MW (1997) — Use of insulin as an anabolic agent. Br J Sports Med
1997PMID 9429012, early UK warning
Heitkamp HC, et al. (2020) — Insulin abuse in bodybuilding: A systematic review. Substance Use & Misuse review series
2020PMID 32310028, modern systematic look
Konstantakos EK, Lord PF (2007) — Insulin abuse in athletes. Metab Syndr Relat Disord
2007PMID 18370811
Holt RIG, Sönksen PH (2008) — Growth hormone, IGF-I and insulin and their abuse in sport. Br J Pharmacol
2008PMID 18454170, GH-IGF-insulin triad context